Uniqure nv QURE.US Overview Analysis
QURE AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
QURE Current Performance
21.77%
Uniqure nv
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to QURE
- MGX Metagenomi incValue -Trend 3Swing Trading 2Whale Interest 1Dividend 1See more
QURE Profile
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company's lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington's disease is in Phase I/II clinical study.